Preparation method of retroviral vector with CAR (chimeric antigen receptor) as well as vector and application of retroviral vector

By constructing a BaEV retroviral stable packaging cell line, the problem of low transduction efficiency of NK cells was solved, and efficient and low-cost large-scale production was achieved, and the transduction efficiency and cell health were taken into account.

CN118995822APending Publication Date: 2024-11-22SHENZHEN CELL VALLEY BIOMEDICAL CO LTD +1
View PDF 0 Cites 6 Cited by

Patent Information

Application Number
CN202411134531.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-17
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

In the prior art, the transduction efficiency of NK cells is low, especially when using VSVG envelope lentiviral vectors, the transduction efficiency is extremely low, and there are safety risks and high costs, making it difficult to meet the needs of large-scale industrial applications.

Method used

Constructing the BaEV retroviral stable packaging cell line, and by constructing gag-pol and ASCT-1/2 receptor knockout in the HEK293T cell line, combining BaEV envelope protein, the BaEV-PackRV cell line was developed to achieve efficient production and transformation guide.

Benefits of technology

It significantly improves the transduction efficiency of NK cells and T cells, reduces the cost of virus preparation, achieves high-quality and large-scale production, the positive rate of transduction can reach 90%, and maintains cell viability and amplification ability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118995822A_ABST
    Figure CN118995822A_ABST
Patent Text Reader

Abstract

The invention provides a preparation method of a retroviral vector with a CAR (chimeric antigen receptor) as well as the vector and application thereof, the method comprises the preparation method of the retroviral vector with the CAR, the method comprises the following steps: constructing a BaEV retrovirus stable packaging cell line, transfecting a virus with a retroviral vector plasmid with the CAR to prepare a cell line, and screening the cell line to obtain the retroviral vector with the CAR. According to the method, a BaEV retrovirus stable packaging cell line is transduced by the retrovirus vector, so that a stable BaEV-CAR retrovirus vector packaging cell line is obtained. According to the present invention, the efficient transduction of the NK cells, the T cells and other difficult-to-transduction primary immune cells can be achieved under the low MOI, the transduction positive rate can be as high as 90% and can be maintained stable, and the ultrahigh transduction efficiency does not affect the motility and the amplification of the NK cells and the T cells.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of cell therapy, and in particular to a method for preparing a retroviral vector having CAR, and a vector and use thereof. Background Art

[0002] At present, the development of CAR-T and CAR-NK products faces the following challenges in terms of underlying technology: low transduction efficiency, poor amplification multiples, and poor cryopreservation. Among them, efficient transduction of NK cells is the bottleneck of CAR-NK development. As a natural immune barrier, NK cells are naturally resistant to infection and are not easily transduced by viruses. Currently, lentiviral vectors are commonly used on the market to transduce NK cells, and lentiviral vectors usually use VSVG envelopes. Although the receptor low-density lipoprotein (LDL) of the VSVG envelope is expressed in large quantities on activated T cells, it is less expressed on activated NK cells. At present, the application of mature VSV-G (pseudo-lentivirus packaged with VSV-G (vesicular stomatitis virus envelope glycoprotein)) is not enough to solve the above-mentioned transduction and genetic manipulation problems. A large number of studies have shown that the efficiency of VSV-G lentivirus transduction of NK cells is extremely low (only 5-10%), and the reason for this phenomenon is most likely because NK cells have natural antiviral ability. In view of the low efficiency of VSVG enveloped lentiviral vector transduction of NK, some studies have used small molecule inhibitors to upregulate the expression of LDL-R (low-density lipoprotein receptor) on the surface of NK cells to increase the transduction efficiency of VSVG enveloped lentivirus, and some studies have used BX795 to inhibit NK antiviral signals to increase the transduction efficiency of NK. However, they all face the disadvantages of unstable CAR positivity and high toxicity, which is not conducive to the expansion of CAR-NK cells and cannot be applied in large-scale and stable clinical applications. In particular, BX795 will have a certain impact on the killing function and proliferation ability of NK cells, which obviously does not meet the requirements of clinical application. Studies have shown that some retroviruses can efficiently transduce NK cells, but there are certain risks in the safety of retroviral insertion sites.

[0003] Patent WO2013 / 045639A1 discloses that a modified lentivirus (BaEV lentivirus) packaged with baboon endogenous retrovirus (BaEV) envelope glycoprotein can efficiently transduce T cells and B cells. Although BaEV envelope glycoprotein (BaEV-G) has extremely high application value, it is difficult to produce high-titer pseudoviral particles from BaEV envelope glycoprotein. CN117467705 A discloses an efficient BaEV envelope virus packaging method, which includes introducing BaEV envelope glycoprotein or a vector containing BaEV envelope glycoprotein encoding nucleic acid, target gene encoding nucleic acid and viral packaging elements into target cells; or constructing a cell line that stably expresses BaEV envelope glycoprotein, and introducing target gene encoding nucleic acid and viral packaging elements into the cell line.

[0004] In order to improve the transduction efficiency of NK cells, the most common method currently is to use other envelope proteins to construct lentiviral vectors. Studies have shown that baboon endogenous retrovirus (BaEV) envelope glycoprotein pseudotyped lentiviral vector (BaEV-LV) can significantly improve the transduction efficiency of NK cells, and its transduction efficiency is better than that of VSVG-LV vector.

[0005] At present, most BaEV enveloped lentiviral vectors and BaEV enveloped retroviral vectors can only produce pseudoviruses by transiently transfecting expression plasmids and packaging plasmids into HEK293T cells, which is inefficient and has problems such as DNA residues, resulting in cumbersome subsequent purification processes and unstable virus titers and virus quality between batches. This method of transient transfection to prepare BaEV pseudoviruses cannot produce high-quality pseudoviruses in large quantities and stably, and is difficult to apply on a large scale, resulting in high initial R&D and industrialization costs for pseudovirus preparation.

[0006] Currently, the BaEV envelope glycoprotein used for lentivirus packaging mainly has the following forms: 1. Wild-type BaEV-WT; 2. BaEV-Rless, that is, the BaEV envelope glycoprotein form without fusion restrictive R peptide; 3. BaEV / TR, that is, the BaEV envelope glycoprotein form in which the wild-type BaEV-WT cell tail domain is replaced with the MLV envelope glycoprotein cell tail domain. Compared with BaEV-Rless, the BaEV / TR form has greatly reduced cytotoxicity and greatly reduces the appearance of syncytia during virus packaging, but the virus titer is lower than that of the BaEV-Rless form. It is reported that BaEV-Rless can improve the transduction efficiency of primary cells compared with wild-type BaEV-WT. The specific forms of "BaEVRLess" and "BaEV / TR" are described in detail in Chinese patent CN104080917B.

[0007] Currently, there is a PG13 stable packaging retroviral cell line on the market, which can produce retroviral vectors in large quantities and stably, and the viral envelope is GALV (Gibbon Ape Leukemia Virus). The GALV retroviral vector prepared by this system can achieve a transduction efficiency of more than 60% for T cells, but the transduction efficiency for NK cells is only about 20% and is limited by the size and structural complexity of the target gene. Therefore, it cannot fully meet the requirements of the field of cell therapy for efficient transduction of other difficult-to-transduce primary immune cells such as T cells and NK cells. Summary of the invention

[0008] In order to solve the above problems, the present invention provides a method for preparing a retroviral vector with CAR, the method comprising the following steps: Step 1: constructing a BaEV retroviral stable packaging cell line; Step 2: transfecting a retroviral vector plasmid with CAR to prepare a cell line to harvest a transiently transfected retroviral vector; and Step 3: transducing the retroviral vector obtained in step 2 into the BaEV retroviral stable packaging cell line obtained in step 1 to obtain a stable BaEV-CAR retroviral vector packaging cell line. The term "chimeric antigen receptor" or "CAR" refers to a group of engineered polypeptides or proteins that, when in immune effector cells, bind to specific antigens contained on target cells, and generate intracellular signals after recognizing the specific antigens, activating the downstream pathways of the cells where the receptors are located, so as to initiate the killing effect of the immune effector cells on the target cells. The immune effector cells include but are not limited to NK cells, macrophages, neutrophils, T cells, and the like. CAR generally includes at least one extracellular antigen binding domain, a transmembrane domain, and a cytoplasmic signaling domain, as described in CN117467705A.

[0009] In one embodiment, step 1 includes the following steps: Step 11: transferring the structural protein gag-pol protein required for constructing a retrovirus into a HEK293T cell line or a cell line derived therefrom to obtain a corresponding cell line containing the structural protein gag-pol protein; Step 12: based on the cell line obtained in step 11, constructing a HEK293T cell line or a cell line derived therefrom in which both ASCT-1 and ASCT-2 receptor proteins are simultaneously knocked out to obtain a cell line in which both ASCT-1 and ASCT-2 receptor proteins are knocked out; Step 13: transferring the BaEV virus envelope into the cell line obtained in step 12 to obtain the BaEV retrovirus stable packaging cell line.

[0010] In one embodiment, the step 11 comprises: step 111, transfecting a HEK293T cell line or a cell line derived therefrom with a gag-pol plasmid; step 112, adding antibiotics after transfection to screen a HEK293T cell line or a cell line derived therefrom that highly expresses the gag-pol target gene; step 113, digesting the HEK293T cell line or a cell line derived therefrom obtained in step 112, culturing the digested cells, and selecting monoclonal cells; step 114, performing a transient transfection toxin production titer test on the monoclonal cells obtained in step 113, screening monoclonal cells with a high toxin production titer, and obtaining a corresponding cell line containing the structural protein gag-pol protein.

[0011] In one embodiment, the step 12 comprises: step 121, knocking out the ASCT-1 gene in the cells containing the structural protein gag-pol protein obtained in step 11; step 122, flow sorting and culturing the cells obtained in step 121 to obtain monoclonal cells; step 123, selecting the monoclonal cells obtained in step 122, performing target detection, and obtaining monoclonal cells with homozygous knockout of the ASCT-1 gene; and step 124, knocking out two exons of the ASCT-2 gene in the monoclonal cells obtained in step 123, and further selecting monoclonal cells to obtain cells with knockout of ASCT-1 and ASCT-2 receptor proteins.

[0012] In one embodiment, the step 13 includes: step 131, transfecting the ASCT-1 and ASCT-2 receptor protein knockout cells obtained in step 12 with the BaEV envelope plasmid; step 132, after transfection, adding antibiotics to screen for retroviral vector packaging cell lines that highly express the BaEV envelope; step 133, digesting the BaEV enveloped retroviral vector packaging cell lines obtained in step 132, culturing the digested cells, and selecting monoclonal cells; and step 134, performing a transient toxin production titer test on the monoclonal cells obtained in step 133, screening monoclonal cells with high toxin production titers, and obtaining the BaEV retrovirus stable packaging cell line.

[0013] In one embodiment, in step 131, the BaEV envelope plasmid is a wild-type BaEV envelope plasmid or a BaEV-Rless envelope plasmid.

[0014] In one embodiment, the virus production cell line in step 2 is a HEK293T cell line or a cell line derived therefrom.

[0015] In one embodiment, in step 3, the retroviral vector obtained in step 2 is mixed with the BaEV retroviral stable packaging cell line obtained in step 1, and horizontal centrifugation is performed to promote transduction of the BaEV retroviral stable packaging cell line by the retroviral vector.

[0016] In one embodiment, a retroviral vector produced according to the above method is provided.

[0017] In one embodiment, there is provided use of the above-mentioned retroviral vector in the preparation of a cell therapy drug.

[0018] In one embodiment, a method for preparing immune effector cells comprising CAR is provided, the method comprising transfecting the immune effector cells with the retroviral vector described above.

[0019] In one embodiment, the immune effector cells include NK cells, T cells, macrophages, or neutrophils.

[0020] In one embodiment, an immune effector cell comprising CAR is prepared according to the above method.

[0021] In one embodiment, the use of the above-mentioned immune effector cells in the preparation of cell therapy drugs is provided.

[0022] The present invention is the first to transfer the structural protein gag-pol and BaEV envelope protein required for the preparation of retrovirus into HEK293T cells to enable their stable expression.

[0023] The present invention knocks out the ASCT-1 / 2 receptors of HEK293T cells for the first time, which solves the problem of cell-cell fusion and syncytium formation induced by BaEV envelope, allowing cells to produce toxins normally; on the other hand, it avoids repeated infection of cells themselves by BaEV envelope retrovirus, causing cell death. After knocking out the ASCT1 / 2 receptors, cells are no longer affected by viral infection, can continue to grow, and continue to produce toxins.

[0024] The present invention develops a stable packaging cell line (BaEV-PackRV) that can stably and mass-produce BaEV retroviral vectors. This packaging cell line has provided retroviral gag, pol and envelope protein (BaEV) to mediate the packaging and transcription of the target gene. The plasmid containing the target gene is first transiently transfected with Phoenix-Ampho, and the supernatant is collected to transduce BaEV-PackRV, thereby obtaining a stable toxin-producing production cell line. Therefore, only a small amount of plasmid is used for the production of retroviral vectors in the first step of transient transfection, which saves a large number of plasmid preparation and purification processes. For subsequent virus preparation, it is only necessary to resuscitate the toxin-producing cell line and collect the cell culture supernatant, which is the required retroviral vector. Using the BaEV stable packaging cell line as the production raw material for retroviral vectors greatly reduces the cost of virus preparation; reducing impurities and downstream purification processes, the cost of virus preparation for cell therapy products is reduced by more than 10 times.

[0025] In addition, the expression level of envelope receptors on NK cells is correlated with the efficiency of viral integration. The BaEV envelope receptors are neutral amino acid transporters ASCT-1 and ASCT-2 (ASCT-1 / 2), both of which are highly expressed on activated NK cells, facilitating efficient viral infection of NK cells and thus improving the transduction efficiency of NK cells.

[0026] The present invention prepares a BaEV retrovirus stable packaging cell line (BaEV-PackRV) for low-cost, high-quality and efficient large-scale industrial preparation of pseudoviruses and their application in efficient transduction of cell therapy products. Compared with the transiently transfected BaEV lentivirus, high-titer virus vectors can be produced without multi-plasmid transfection, the production process is simpler, the cost is lower, the product quality can be better controlled and large-scale production can be carried out; compared with the stably packaged GALV retrovirus, efficient transduction of difficult-to-transduce primary immune cells such as NK cells and T cells can be achieved at a lower MOI, the transduction positive rate can be as high as 90% and maintained stable, and the ultra-high transduction efficiency does not affect the viability and amplification of NK cells and T cells. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] In order to more clearly illustrate the technical solutions in the embodiments of the present application, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments recorded in the present application. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative work.

[0028] Figure 1 is a flowchart of the construction of BaEV retrovirus stable packaging cells of the present invention;

[0029] Figure 2 This is the result of RT-PCR detection of the relative expression level of gag-pol in HEK293T-gag-pol monoclonal cells;

[0030] Figure 3 It is the same as the flow cytometry chart of HEK293T-gag-pol monoclonal cell toxin titer detection;

[0031] Figure 4 It was identified by sequencing of HEK293T-gag-pol-ASCT-1-KO homozygous knockout monoclonal cells, and 8 ASCT-1 gene knockout homozygous cells were screened;

[0032] Figure 5 This is the result of Western blot verification of the expression of ASCT-1 gene in homozygous knockout monoclonal cells;

[0033] Figure 6This is the result diagram of sequencing verification of ASCT-2 receptor knockout;

[0034] Figure 7 This is the result of PCR detection of exon knockout in HEK293T-gag-pol-ASCT-1-KO monoclonal cells;

[0035] Figure 8 The BaEV envelope plasmid was transfected into HEK293T-gag-pol-ASCT-1&2-KO and HEK293T cells respectively, and the growth status of the two cells was recorded by taking photos under a microscope 24 hours later;

[0036] Fig. 9 This is the result of RT-PCR detection of BaEV envelope copy number of BaEV-expressing monoclonal cells after transfection of BaEV envelope plasmid into HEK293T-gag-pol-ASCT-1&2-KO cells;

[0037] Fig.10 The cells with a high copy number of BaEV envelope were selected and counted every two days to draw a growth curve.

[0038] Fig.11 This is the flow cytometry graph of the transient toxin production titer detection of BaEV-Rless-57 and BaEV-WT-64;

[0039] Fig.12 This is a graph showing the transduction positive rate results of the BaEV-Rless-57-copGFP and BaEV-WT-64-copGFP toxin-producing cell lines detected by flow cytometry;

[0040] Fig.13 This is the result of the transduction positive rate of BaEV-Rless-57-copGFP and BaEV-WT-64-copGFP stable transfection toxin production titer

[0041] Fig.14 This is the result graph of the positive rate of GALV-CD19 CAR and BaEV-CD19 CAR transduced T cells;

[0042] Fig.15 It is the CAR-T cell proliferation fold curve;

[0043] Fig.16 This is the result graph of the positive rate of NK cells transduced by GALV-CD19 CAR and BaEV-CD19 CAR;

[0044] Fig.17 It is a CAR-NK cell proliferation multiple curve. DETAILED DESCRIPTION

[0045] In order to enable those skilled in the art to better understand the technical solutions in this application, the present invention will be further described below in conjunction with embodiments. Obviously, the described embodiments are only part of the embodiments of this application, rather than all of the embodiments. Based on the embodiments in this application, all other embodiments obtained by ordinary technicians in this field without creative work should fall within the scope of protection of this application.

[0046] Cell sources: HEK293T, Phoenix-Ampho, Phoenix-ECO, and PG13 cells are all commercial cell lines purchased from ATCC. Plasmid sources: pCMV-MMLV-gag-pol-PGK-puro, pMFG-CD19 CAR, pMFG-copGFP, pCMV-BaEV-Rless-PGK-hygr-PA, pCMV-BaEV-WT-PGK-hygr-PA, and PX458 plasmids are all commercial plasmids purchased from Guangdong Junhou Biopharmaceutical Co., Ltd. The reagents and raw materials used in the present invention are all from commercial reagents unless otherwise specified.

[0047] The present invention provides a method for constructing a BaEV retrovirus packaging cell line. Figure 1 The specific method is described as follows.

[0048] Example 1 Construction and screening of HEK293T-gag-pol cells

[0049] 1. HEK293T cell recovery and plating

[0050] HEK293T cells were revived in DMEM containing 10% FBS and cultured in a 5% CO2 cell culture incubator for 48 h. When the cell confluence reached about 80%, the cells were digested and 8×10 5 The cells were seeded in 6-well plates and cultured in a 37°C, 5% CO2 incubator.

[0051] 2. pCMV-MMLV-gag-pol-PGK-puro plasmid transfection

[0052] After HEK293T cells were plated for 24 hours, the cell confluence was observed under a microscope to reach 70-80%, and then transfection was performed. Prepare the transfection system: 3.3 μg of pCMV-MMLV-gag-pol-PGK-puro plasmid, 3:1 ratio of Fugene HD: DNA, and DMEM medium to 200 μL. After mixing, let stand at room temperature for 15 minutes, add 200 μL to each well, and culture in a 37°C, 5% CO2 incubator.

[0053] 3. Puromycin screening:

[0054] 24 hours after transfection, the medium was replaced with DMEM complete medium containing 3 μg / mL puromycin, and the cells were treated every two days. After the medium was changed, the screening concentration of puromycin was maintained at 3 μg / mL. After one week of drug screening, the cells were treated every four days, and after the medium was changed, puromycin was used for screening at a final concentration of 8 μg / mL to obtain HEK293T-gag-pol cells that highly expressed the gag-pol target gene.

[0055] 4. Select monoclonal cells:

[0056] HEK293T-gag-pol cells were digested, the cell density was adjusted to 100 cells / mL, and the cells were inoculated into 96-well plates. 100uL of cell suspension was added to each well, and the cells were cultured in a 37°C, 5% CO2 incubator. The cell growth status was monitored, and the monoclonal cells were gradually expanded.

[0057] 5. Monoclonal cell identification:

[0058] Extract RNA from monoclonal cells and reversely obtain cDNA, and perform RT-PCR to detect the expression of gag-pol ( Figure 2 ). The gag-pol primers were gag-pol-qPCR-F: gacggaaatggtggaga; gag-pol-qPCR-R: atgcctgcgaggtagtg.

[0059] Figure 2 It shows the gag-pol gene expression levels of different monoclonal cells, but it cannot represent the gag-pol protein expression level and protein function. Therefore, we selected 6 monoclonal cell lines with high expression (clone 2), medium expression (clone 10, clone 19, clone 28), and low expression (clone 1, clone 14) of gag-pol gene for transient transfection and toxin production test.

[0060] 6. Toxin production by HEK293T-gag-pol monoclonal cells:

[0061] The above 6 monoclonal cells were selected for transient transfection and toxin production test. The transfection method was the same as above. Prepare the transfection system: the amount of pMFG-copGFP plasmid was 1μg, the amount of pCMV-BaEV-Rless-PGK-hygr-PA or pCMV-BaEV-WT-PGK-hygr-PA plasmid was 500ng respectively, and the DMEM medium was filled to 100μL. After 24h of transfection, fresh DMEM complete medium was replaced and placed in a 32℃ incubator for toxin production. After 48h, the cell supernatants were collected respectively, and the cell supernatants were filtered with a 0.45μm filter membrane for titer detection.

[0062] 7. Detection of toxin titer produced by transient transfection of HEK293T-gag-pol monoclonal cells:

[0063] HEK293T cells were seeded in 24-well plates at 2 × 10 5 After 24 hours, discard the cell culture medium, add 1mL of the virus solution to be tested, then add 1μg / mL polybrene, centrifuge at 32℃2500rpm for 1h. Continue to culture in a 37℃ incubator. After 24 hours of viral transduction, replace with fresh culture medium. After 48 hours, flow cytometry is used to detect the transduction efficiency ( Figure 3 ). Calculation method of virus biological titer: virus titer (TU / mL) = number of cells infected * percentage of positive cells / volume of virus stock solution (Table 1). Flow cytometry detected the infection positive rate of retrovirus produced by HEK293T-gag-pol monoclonal cells transiently transformed into HEK293T cells at different dilution ratios, which reflects the biological titer of the virus.

[0064] Transient transfection and toxin production tests were performed on the 6 selected HEK293T-gag-pol monoclonal cells, among which HEK293T-gag-pol-Clone 1 had a higher toxin production titer. Subsequently, Clone 1 cells will be selected for KO cell line construction.

[0065] Table 1: Detection of toxin titer of different HEK293T-gag-pol monoclonal cells

[0066] Transduction positive rate Virus titer (TU / mL) Clone 1 62.8% 1.54E+06 Clone 2 8.38% 2.05E+05 Clone 10 9.69% 2.37E+05 Clone 14 6.71% 1.64E+05 Clone 19 15.8% 3.87E+05 Clone 28 44.8% 1.10E+06

[0067] Example 2 Construction of HEK293T-gag-pol-ASCT-1&2-KO cell line

[0068] 1. Plasmid construction:

[0069] Design ASCT-1-gRNA and ASCT-2-gRNA fragments, and synthesize primers. See Table 2 for primer sequences. Form the target fragment by self-ligation of primers. Double-digest the PX458 plasmid with BbsI restriction endonuclease, recover and purify. Seamlessly clone the target fragment and linearized vector, transform the product into DH5α Escherichia coli, shake the bacteria and plate and culture overnight, pick the single clone colony for shaking, sequencing and double-digestion verification.

[0070] Table 2 Primer sequences

[0071]

[0072]

[0073] 2. HEK293T-gag-pol knockout of ASCT-1 gene:

[0074] Add 3 μg of PX458-ASCT-1-gRNA plasmid to 150 μl of electroporation buffer to prepare electroporation reaction solution. 6 HEK293T-gag-pol-Clone 1 was centrifuged and the supernatant was discarded. After adding the electroporation reaction solution, it was gently blown and transferred to the electroporation cup. The electroporation was performed using the Lonza 2b electroporator with the electroporation program Q-001. After the end, the cell suspension in the electroporation cup was aspirated and added to the preheated DMEM medium for continued culture. The PX458-ASCT-1-gRNA plasmid was GFP-tagged and transiently expressed after electroporation of HEK293T-gag-pol-Clone 1. GFP-positive cells were sorted by flow cytometry after 24 hours.

[0075] 3. Select monoclonal cells:

[0076] Adjust the density of flow-sorted GFP cells to 100 cells / mL, inoculate them into 96-well plates, add 100uL of cell suspension to each well, and culture the cells in a 37°C, 5% CO2 incubator. Monitor the cell growth status, gradually expand the monoclonal cells, and expand and verify them after the cells are fully grown.

[0077] 4. Targeting detection of HEK293T-gag-pol-ASCT-1-KO monoclonal cells:

[0078] DNA of monoclonal cells was extracted and PCR was performed to detect the expression of ASCT-1 gene. The primers of ASCT-1 were ASCT-1-F: ggtctgagacaagacacatg; ASCT-1-R: gtcactctaagggatggcag. The PCR products were sequenced and the results were compared with the website https: / / decodr.org / . Sequencing revealed 8 homozygous knockout clones ( Figure 4 ). HEK293T-gag-pol-ASCT-1-KO homozygous knockout monoclonal cells were sequenced and identified, and 8 homozygous ASCT-1 gene knockout cells were screened. Eight homozygous knockout clones were selected for Western blot verification of ASCT-1 gene expression. Figure 5 Western blot results showed that the ASCT1 gene was not expressed in HEK293T-gag-pol-ASCT-1-KO-Clone-30 cells, so Clone-30 was selected to knock out the ASCT-2 gene.

[0079] 5. HEK293T-gag-pol-ASCT-1-KO knockout of ASCT-2 gene:

[0080] HEK293T-gag-pol-ASCT-1-KO-Clone-30 cells were electroporated with PX458-ASCT-2-gRNA-1 plasmid and PX458-ASCT-2-gRNA-2 plasmid to knock out the two exons of the ASCT-2 gene, and monoclonal cells were further selected using the same method as before. The genome of the monoclonal cells was extracted and sequenced using 1-ASCT-2-F. In order to ensure that all transcripts of the ASCT-2 protein were destroyed, 8 clones with deletion fragments greater than 5000 bp were screened, and Clone-30, 47, 51, and 58 were selected for the next PCR verification experiment.

[0081] According to the PCR results in the figure, the PCR results of the three pairs of primers of the HEK293T-gag-pol-ASCT-1-KO-Clone-47 clone were all negative, indicating that the ASCT-2 gene knockout of the Clone-47 monoclonal cell was successful, so Clone-47 was selected for the next experiment. Sequencing verified the knockout of the ASCT-2 receptor, such as Figure 6 As shown, the genome of monoclonal cells was extracted and sequenced to verify the knockout of ASCT-2 receptor. A total of 8 HEK293T-gag-pol-ASCT-1-KO monoclonal cells with deletion fragments greater than 5000 were screened. The Western blot results are shown in Figure 7 As shown, three pairs of primers were used to detect the knockout of two exons of the ASCT02 gene. The PCR test results showed that all transcripts of the ASCT-2 protein in Clone-47 single cells were destroyed. The PCR detection primers for ASCT-2 are shown in Table 3.

[0082] Table 3 PCR primers for ASCT-2

[0083]

[0084] Example 3 Construction of BaEV stable packaging cell line

[0085] 1. Transfection of BaEV envelope plasmid into HEK293T-gag-pol-ASCT-1&2-KO cells:

[0086] The above HEK293T-gag-pol-ASCT-1&2-KO-clone-47 cells were seeded in a six-well plate. After 24 hours of cell plating, the cell confluence was observed under a microscope to reach 70-80%. pCMV-BaEV-Rless-PGK-hygr-PA and pCMV-BaEV-WT-PGK-hygr-PA were transfected into HEK293T-gag-pol-ASCT-1&2-KO cells respectively. Prepare the transfection system: the amount of plasmid was 3.3μg, the ratio of Fugene HD: DNA was 3:1, and the DMEM medium was filled to 200μL. After mixing, let it stand at room temperature for 15 minutes, add 200μL to each well, and culture it in a 37℃, 5% CO2 incubator.

[0087] 24h after transfection, the growth status of the two cells was recorded by microscope. Figure 8 ). After transfection, the cell status of HEK293T-ASCT-1&2-KO cells was significantly better than that of wild-type HEK293T cells. After knocking out the ASCT-1 and ASCT-2 genes, the problem of syncytia formation after BaEV transfection and inability to produce toxins normally was solved.

[0088] 2. Hygromycin screening:

[0089] 24 hours after transfection, the medium was replaced with DMEM complete medium containing 3 μg / mL hygromycin, and the cells were treated every two days. After the medium was changed, the hygromycin screening concentration was maintained at 300 μg / mL. After one week of drug screening, the cells were treated every four days, and after the medium was changed, puromycin was used for screening at a final concentration of 800 μg / mL to obtain a retroviral vector packaging cell line that highly expressed the BaEV-WT or BaEV-Rless target gene.

[0090] 3. Picking single clones:

[0091] Digest the cells selected by hygromycin, adjust the cell density to 100 cells / mL, inoculate into 96-well plates, add 100uL of cell suspension to each well, and culture the cells in a 37°C, 5% CO2 incubator. Monitor the cell growth status, gradually expand the monoclonal cells and freeze them.

[0092] 4. Detection of BaEV envelope copy number in monoclonal cells:

[0093] Single-cell RNA was extracted and reversed to obtain cDNA, and RT-PCR was performed to detect the expression of BaEV-Rless or BaEV-WT envelope. The primers for BaEV envelope detection were BaEV-qPCR-F: ggcatacacttatctacccacgaac; BaEV-qPCR-R: tgatcaatagcagggatggggac. The RT-PCR reaction system was prepared according to Table 4. 15 μL of the mixed solution was drawn into 8 consecutive PCR reaction wells, with 3 replicate wells in each group. The fluorescent PCR amplification program was set up according to Table 5. In addition, the BaEV plasmid was used as a positive quality control, and its copy number was calculated: (6.02×10 23 times copy number / mole)×(ng / μL×10 9 ) / (DNA length × 660) = copies / μL, and a standard curve was drawn. According to the standard curve, the number of BaEV envelope copies of each monoclonal cell was calculated ( Fig. 9 ).

[0094] Fig. 9 The copy number levels of BaEV envelope in different monoclonal cells are shown. In BaEV-Rless cells, the R57 (BaEV-Rless-57) monoclonal envelope expression level is the highest; in BaEV-WT cells, the W64 (BaEV-WT-64) monoclonal envelope expression level is the highest.

[0095] Table 4: RT-PCR reaction system

[0096] composition volume Final concentration 2×Mix 10μL / 10μM Primer(F) 0.5μL 0.25μM 10μM Primer(R) 0.5μL 0.25μM Enzyme-free water 4μL / Template DNA 5μL / Total 20μL /

[0097] Table 5: RT-PCR reaction procedure

[0098]

[0099] 5. Drawing of monoclonal cell growth curve:

[0100] The top five monoclonal cells with the highest number of BaEV-Rless and BaEV-WT envelope copies were selected, and 4 × 10 5 The cells were inoculated in six-well plates, and HEK293T cells were used as controls. The cells were counted every two days and the growth curve was drawn. Fig.10 ). The doubling time of all monoclonal cells was delayed compared with HEK293T. Among them, BaEV-WT-64 and BaEV-Rless-57 grew faster and were subsequently tested for their toxin production ability.

[0101] 6. Detection of the ability of monoclonal cell transient transfection to produce toxins:

[0102] The above-mentioned two monoclonal cells of BaEV-Rless-57 and BaEV-WT-64 were selected for transient transfection and toxin production test. The two cells were inoculated into six-well plates respectively and transfected after 24 hours. Prepare the transfection system: the amount of pMFG-copGFP plasmid is 3.3μg, the ratio of Fugene HD: DNA is 3:1, and the DMEM medium is filled to 200μL. After mixing, let it stand at room temperature for 15 minutes, add 200μL to each well, and culture it in a 37℃, 5% CO2 incubator. After 24 hours of transfection, replace with fresh DMEM complete medium and place it in a 32℃ incubator for toxin production. After 48 hours, collect the cell supernatant, filter the cell culture supernatant with a 0.45μm filter membrane and perform titer detection.

[0103] 7. Titer detection:

[0104] HEK293T cells were seeded in 24-well plates at 2 × 10 5 cells. After 24 hours, discard the cell culture medium, add 1mL of the virus to be tested, then add 1μg / mL of polybrene, and centrifuge at 32℃2500rpm for 1h. Place in a 37℃ incubator and continue to culture. After 24 hours of viral transduction, replace with fresh culture medium. After 48 hours, flow cytometry is used to detect the GFP positive rate to calculate the transduction efficiency ( Fig.11 ), flow cytometry was used to detect the infection positive rate of retrovirus produced by BaEV-Rless-57 and BaEV-WT-64 monoclonal cells transiently transfected with pMFG-copGFP in HEK293T cells, which reflects the biological titer of the virus. Virus titer calculation method: virus titer (TU / mL) = number of cells infected × percentage of positive cells / volume of virus stock solution (Table VI).

[0105] No syncytia were found in BaEV-WT-64 and BaEV-Rless-57 cells during transient virus production. According to the virus production titer test, the virus titer packaged by BaEV-WT-64 was higher than that of BaEV-Rless-57, and the stable virus production test was performed later.

[0106] Table 6: Results of transient transfection titer detection of BaEV-Rless-57 and BaEV-WT-64

[0107] Positive rate Titer (TU / mL) BaEV-Rless-57 9.52% 3.8e5 BaEV-WT-64 21.8% 8.72e5

[0108] Example 4 Construction of BaEV-copGFP retroviral vector packaging cell line

[0109] 1. Preparation of BaEV-copGFP retroviral vector:

[0110] A "two-step method" was adopted to construct BaEV-Rless-copGFP and BaEV-WT-copGFP toxin-producing cell lines, using Phoenix-Ampho and BaEV-Rless / BaEV-WT retroviral vector packaging cell lines in turn. The pMFG-copGFP plasmid was transfected into Phoenix-Ampho cells and the cell supernatant was collected to harvest the ecotropic retroviral vector. It was mixed with BaEV-Rless / BaEV-WT cells and horizontal centrifugation was used to promote the transduction of retroviral vectors into BaEV cells to obtain a stable BaEV retroviral vector packaging cell line. The transduction positive rate of BaEV-Rless-copGFP cells and BaEV-WT-copGFP cells was detected by flow cytometry, and the transduction positive rate of both cells reached 60% ( Fig.12 ), and virus preparation can be performed subsequently.

[0111] 2. Preparation and titer detection of BaEV-copGFP retroviral vector:

[0112] BaEV-Rless-57-copGFP cells and BaEV-WT-64-copGFP cells were expanded to T75 culture flasks and placed in a 32°C incubator for toxin production. After 48 hours, the cell culture supernatants were collected and filtered through a 0.45 μm filter membrane for titer detection ( Fig.13 ), flow cytometry detection of the infection positivity rate of BaEV-Rless-57-copGFP and BaEV-WT-64-copGFP stably produced retroviruses on HEK293T cells reflects the biological titer of the virus. Virus titer calculation method: virus titer (TU / mL) = number of cells infected × percentage of positive cells / volume of virus stock solution (Table VI). The transient and stable toxin production titers of BaEV-WT-64 cells are higher than those of BaEV-Rless-57. Subsequently, BaEV-WT-64 was selected as the BaEV retroviral vector packaging cell line (BaEV-PackRV). The results of the stable toxin production titer detection of BaEV-Rless-57-copGFP and BaEV-WT-64-copGFP are shown in Table VII. Table VII: Results of the stable toxin production titer detection of BaEV-Rless-57-copGFP and BaEV-WT-64-copGFP

[0113] Positive rate Titer (TU / mL) BaEV-Rless-57-copGFP 2.42% 9.68e5 BaEV-WT-64-copGFP 17.7% 1.4e6

[0114] Example 5 Construction of BaEV-CD19 CAR and GALV-CD19 CAR toxin-producing cell lines and virus preparation

[0115] 1. Construction of BaEV-CD19 CAR toxin-producing cell line

[0116] According to the method of "Construction of BaEV-copGFP Retroviral Vector Packaging Cell Line" mentioned above, the pMFG-CD19CAR plasmid is transfected into a common virus preparation cell line, such as a HEK293T cell line or its derivative cell line, such as Phoenix-Ampho cells, and the cell supernatant is collected to harvest the first step of transiently transfected retroviral vectors. It is mixed with BaEV-PackRV cells and horizontal centrifugation is used to promote the transduction of BaEV stable packaging cell lines with retroviral vectors to obtain a stable BaEV-CD19 CAR retroviral vector packaging cell line. After the cells are expanded, the cell culture supernatant is collected to obtain the retroviral vector for subsequent transduction of T cells.

[0117] 2. Construction of GALV-CD19 CAR toxin-producing cell line

[0118] Phoenix-ECO and PG13 retroviral vector packaging cell lines were used in turn according to the method of "Construction of BaEV retroviral vector packaging cell line" above. Phoenix-ECO cells were transfected with pMFG-CD19 CAR plasmid and the cell supernatant was collected to harvest the ecotropic retroviral vector. It was mixed with PG13 cells and horizontal centrifugation was used to promote the transduction of retroviral vectors into PG13 cells to obtain a stable GALV-CD19 CAR retroviral vector packaging cell line. Cells were expanded and virus preparation was performed.

[0119] Example 6 BaEV-CD19 CAR, GALV-CD19 CAR transduction T cell test

[0120] 1. Package board:

[0121] RetroNectin (10 μg / mL) was added to a 12-well plate (without tissue treatment), 1 mL per well, and incubated overnight at 4°C in the dark.

[0122] 2. Transduction:

[0123] The next day, remove the RetroNectin solution and rinse with PBS. Use culture medium to dilute the viral vector to prepare the original solution, two-fold and four-fold diluted viral vector suspensions, which are recorded as the original solution, 1:2 dilution and 1:4 dilution groups, respectively. Add 1mL of the above BaEV-CD19 CAR retroviral vector and 1mL of GALV-CD19 CAR retroviral vector to the coated 12-well plate, place it in a 32°C centrifuge, centrifuge at 2500rpm for 1h, and remove the viral supernatant in the well plate. Take 4×10 5After resuspending the activated T cells with 1 mL of BaEV-CD19CAR retroviral vector or 1 mL of GALV-CD19 CAR retroviral vector, the cell suspension was added to the corresponding wells and polybrene (final concentration 6 μg / mL) was added. The 12-well plate was centrifuged at 2500 rpm for 1 hour at 32°C and placed in a 37°C incubator for 2 hours. The supernatant in the well plate was discarded, the corresponding retroviral vector (containing polybrene) was added, and the well plate was placed in a 32°C centrifuge and centrifuged at 2500 rpm for 1 hour. After the end, the cells were placed in a 37°C incubator and incubated for 2 hours.

[0124] 3. Cultivation:

[0125] Discard the supernatant in the well plate, add 1 mL of fresh T cell complete medium to resuspend the cells, add h-IL2 (final concentration 500 U / mL), and continue culturing.

[0126] 4. Transduction positive rate detection:

[0127] 48 h after transduction, 2 × 10 5 After the transduced T cells were incubated with FITC-CD19-FC antigen at 4°C for 30 min, the transduction efficiency of T cells was detected by flow cytometry. Fig.14 ), flow cytometry was used to detect the positive rate of T cell transduction by two retroviruses, GALV-CD19CAR and BaEV-CD19 CAR, according to the original solution, 1:2 dilution, and 1:4 dilution. When the titer of BaEV-CD19 CAR virus was lower than that of GALV-CD19 CAR virus, the positive rate of T cell transduction was significantly higher than that of GALV-CD19 CAR. After the virus was diluted to 4 times, the positive rate of T cell transduction by BaEV-CD19 CAR virus at a lower MOI could maintain the same level as the original solution.

[0128] Each passage took 2 × 10 5 After the transduced CAR-T cells were incubated with FITC-CD19-FC antigen or G4S antibody at 4°C for 30 minutes, the transduction efficiency of T cells was detected by flow cytometry until 8 days after transduction. The CAR positive rate of CAR-T cells remained at the same level as the second day after transduction. The positive rate of GALV-CD19 CAR and BaEV-CD19 CAR transduced T cells is shown in Table 8.

[0129] Table 8: Positive rate of T cells transduced by GALV-CD19 CAR and BaEV-CD19 CAR

[0130]

[0131] 5. Amplification multiple detection:

[0132] After transduction, the proliferation of CAR-T cells was continuously detected until the 8th day after transduction. There was almost no difference in the proliferation times of CAR-T cells transduced with BAEV-CD19-CAR at different dilution multiples and GaLV-CD19-CAR at different dilution multiples. Fig.15 As shown, it shows that BaEV envelope greatly improves the transduction efficiency of retroviral vectors to primary T cells while not affecting the normal proliferation of CAR-T cells.

[0133] Example 7 BaEV-CD19 CAR, GALV-CD19 CAR transduction NK cell test

[0134] 1. Package board:

[0135] RetroNectin (10 μg / mL) was added to a 12-well plate (without tissue treatment), 1 mL per well, and incubated overnight at 4°C in the dark.

[0136] 2. Transduction:

[0137] The next day, remove the RetroNectin solution and rinse with PBS. Use culture medium to dilute the viral vector to prepare the original solution, two-fold and four-fold diluted viral vector suspensions, which are recorded as the original solution, 1:2 dilution and 1:4 dilution groups, respectively. Add 1mL of the above BaEV-CD19 CAR retroviral vector and 1mL of GALV-CD19 CAR retroviral vector to the coated 12-well plate, place it in a 32°C centrifuge, centrifuge at 2500rpm for 1h, and remove the viral supernatant in the well plate. Take 4×10 5 After resuspending the activated NK cells with 1 mL of BaEV-CD19 CAR retroviral vector or 1 mL of GALV-CD19 CAR retroviral vector, the cell suspension was added to the corresponding wells and polybrene (final concentration 6 μg / mL) was added. The 12-well plate was centrifuged at 2500 rpm for 1 hour at 32°C and then placed in a 37°C incubator for 2 hours. The supernatant in the well plate was discarded, the corresponding retroviral vector (containing polybrene) was added, and the well plate was placed in a 32°C centrifuge and centrifuged at 2500 rpm for 1 hour. After the end, the cells were placed in a 37°C incubator and incubated for 2 hours.

[0138] 3. Cultivation:

[0139] Discard the supernatant in the well plate, add 1 mL of fresh NK cell complete medium to resuspend the cells, and continue culturing.

[0140] 4. Transduction positive rate detection:

[0141] 48 h after transduction, 2 × 10 5After the transduced NK cells were incubated with FITC-CD19-FC antigen at 4°C for 30 min, the transduction efficiency of NK cells was detected by flow cytometry. Fig.16 ), flow cytometry was used to detect the positive rate of NK cell transduction by two retroviruses, GALV-CD19 CAR and BaEV-CD19 CAR, according to the original solution, 1:2 dilution, and 1:4 dilution. When the titer of BaEV-CD19 CAR was one-fold lower than that of GALV-CD19 CAR, the positive rate of BaEV-CD19 CAR transducing NK cells was higher than that of GALV-CD19 CAR, and after the virus was diluted 4 times, the transduction positive rate remained stable at more than 90%. However, GALV-CD19 CAR only had a 20% transduction positive rate. In contrast, the BaEV envelope greatly improved the transduction efficiency of retroviral vectors to primary NK cells.

[0142] Each passage took 2 × 10 5 After incubation of the transduced NK cells with FITC-CD19-FC antigen at 4°C for 30 min, the transduction efficiency of NK cells was detected by flow cytometry. 22 days after transduction, the CAR positive rate of CAR-NK transduced with BaEV envelope remained at the same level as the second day after transduction. See Table 9 for the positive rate of NK cells transduced with GALV-CD19 CAR and BaEV-CD19 CAR.

[0143] Table 9: Positive rate of NK cells transduced by GALV-CD19 CAR and BaEV-CD19 CAR

[0144]

[0145] 5. Amplification multiple detection:

[0146] After transduction, the proliferation of CAR-NK cells was continuously monitored until the 22nd day after transduction. There was almost no difference in the proliferation of CAR-NK cells transduced with BAEV-CD19 CAR at different dilution multiples and GaLV-CD19 CAR at different dilution multiples. Fig.17 As shown, it indicates that BaEV envelope greatly improves the transduction efficiency of retroviral vectors to primary NK cells while not affecting the normal proliferation of CAR-NK cells.

[0147] Those skilled in the art will also recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are also intended to be encompassed by the appended claims.

Claims

1. A method for preparing a retroviral vector having a CAR, wherein the method The following steps are involved: Step 1: Construction of BaEV retrovirus stable packaging cell line; Step 2: Transfect the retroviral vector plasmid with CAR into the virus preparation cell line to harvest the transiently transfected retroviral vector; Step 3: The retroviral vector obtained in step 2 is transduced into the BaEV retroviral stable packaging cell line obtained in step 1 to obtain a stable BaEV-CAR retroviral vector packaging cell line.

2. The preparation method according to claim 1, It is characterized in that Step 1 includes the following steps: Step 11: Transform the structural protein gag-pol protein required for the preparation of retrovirus into HEK293T cell line or its derivative cell line to obtain the corresponding cell line containing the structural protein gag-pol protein; Step 12: Based on the cell line obtained in step 11, a HEK293T cell line or a cell line derived therefrom in which both ASCT-1 and ASCT-2 receptor proteins are knocked out is constructed to obtain a cell line in which both ASCT-1 and ASCT-2 receptor proteins are knocked out accordingly; Step 13: The BaEV viral envelope is transferred into the cell line obtained in step 12 to obtain the BaEV retrovirus stable packaging cell line.

3. The preparation method according to claim 2, It is characterized in that The step 11 comprises: Step 111, transfecting HEK293T cell line or its derivative cell line with gag-pol plasmid; Step 112, after transfection, adding antibiotics to screen HEK293T cell lines or cell lines derived therefrom that highly express the gag-pol target gene; Step 113, digesting the HEK293T cell line or its derivative cell line obtained in step 112, culturing the digested cells, and selecting monoclonal cells; Step 114, performing transient toxin production titer test on the monoclonal cells obtained in step 113, screening monoclonal cells with high toxin production titer, and obtaining the corresponding cell line containing the structural protein gag-pol protein.

4. The preparation method according to claim 2, It is characterized in that The step 12 comprises: Step 121, knocking out the ASCT-1 gene in the cells containing the structural protein gag-pol protein obtained in step 11; Step 122, flow sorting and culturing the cells obtained in step 121 to obtain monoclonal cells; Step 123, selecting the monoclonal cells obtained in step 122, performing a targeting test, and obtaining monoclonal cells homozygous for ASCT-1 gene knockout; Step 124, knocking out two exons of the ASCT-2 gene in the monoclonal cells obtained in step 123, and further selecting the monoclonal cells to obtain cells in which the ASCT-1 and ASCT-2 receptor proteins are knocked out.

5. The preparation method according to claim 2, It is characterized in that The step 13 comprises: Step 131, transfecting the ASCT-1 and ASCT-2 receptor protein knockout cells obtained in step 12 with BaEV envelope plasmid; Step 132, after transfection, adding antibiotics to screen for retroviral vector packaging cell lines that highly express the BaEV envelope; Step 133, digesting the BaEV enveloped retroviral vector packaging cell line obtained in step 132, culturing the digested cells, and selecting monoclonal cells; Step 134, performing a transient toxin production titer test on the monoclonal cells obtained in step 133, screening monoclonal cells with high toxin production titers, and obtaining the BaEV retrovirus stable packaging cell line.

6. The preparation method according to claim 5, It is characterized in that In step 131, the BaEV envelope plasmid is a wild-type BaEV envelope plasmid or a BaEV-Rless envelope plasmid.

7. The preparation method according to claim 1, It is characterized in that The virus preparation cell line in step 2 is a HEK293T cell line or a cell line derived therefrom.

8. The preparation method according to claim 1, It is characterized in that In step 3, the retroviral vector obtained in step 2 is mixed with the BaEV retroviral stable packaging cell line obtained in step 1, and horizontal centrifugation is performed to promote transduction of the BaEV retroviral stable packaging cell line by the retroviral vector.

9. A retroviral vector produced according to the method of any one of claims 1 to 8.

10. Use of the retroviral vector according to claim 9 in the preparation of cell therapy drugs.

11. A method for preparing immune effector cells comprising CAR, It is characterized in that The method comprises transfecting immune effector cells with the retroviral vector of claim 9.

12. The preparation method according to claim 1, It is characterized in that The immune effector cells include NK cells, T cells, macrophages or neutrophils.

13. An immune effector cell comprising CAR, It is characterized in that The immune effector cells are prepared according to any one of claims 11-12.

14. Use of the immune effector cells according to claim 13 in the preparation of cell therapy drugs.

Citation Information

Cited By

  • Batch production method of retroviral vector, and vector and application thereof

    CN119020417A

  • CAR-NK cell for treating non-small cell lung cancer and / or esophageal squamous carcinoma as well as application and composition of CAR-NK cell

    CN120192926A

  • Methods of producing engineered viroid particles by stabilizing cell lines and engineered viroid particles thereof

    CN120866241A

  • A method for producing engineered virus-like particles using stable cell lines and the engineered virus-like particles thereof.

    CN120866241B

  • Method for preparing immune cell treatment products in batches without electrotransduction and product thereof

    CN120866421A